News
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?
This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...
CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...
The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.
Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.
Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...
The findings showcased Zepbound's standout efficacy, with participants losing 50.3 lbs on average compared to 33.1 lbs with Wegovy. Additionally, nearly 32 percent of those taking Zepbound ...
Yes, Wegovy is generally more expensive than Zepbound. Without insurance, Wegovy can cost $1,349.02 per month, while Zepbound is typically priced at around $1,059.87 for a 30-day supply if not ...
Wegovy's maker, Novo Nordisk, is charging $499 per month for its direct-to-consumer product. Customers can't get their health insurance to pay for the either Eli Lilly's Zepbound vials or the ...
People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results